浙江司太立制药股份有限公司 第五届董事会第三次会议独立意见 浙江司太立制药股份有限公司 独立董事关于公司第五届董事会第三次会议相关事项的独立意见 浙江司太立制药股份有限公司（以下简称"公司"）第五届董事会第三次会议 于 2023 年 8 月 21 日召开，根据《公司章程》《关于在上市公司建立独立董事制度 的指导意见》等相关规定，我们作为公司独立董事，对会议资料进行了认真审阅， 基于自身的独立判断，现就公司第五届董事会第三次会议审议的相关事项发表如下 独立意见： 一、《关于向关联方转让股权的议案》 （以下无正文） 独立董事：胡吉明、毛美英、章晓科 2023 年 08 月 21 日 1 浙江司太立制药股份有限公司 第五届董事会第三次会议独立意见 [ 本页无正文，为公司第五届董事会第三次会议独立意见之签字页 ] 独立董事： 公司向关联方转让仙居县聚合金融服务有限公司 36%股权，转让符合公司战略 发展方向，不会对公司主营业务造成影响，不会导致公司合并报表范围发生变更。 本次交易价格合理，交易符合市场规则，公平、自愿，不会损害公司及股东，特别 是中小股东的利益。关联董事已回避表决，表决程序符合相关法律、法规和《公司 ...

证券代码：603520 证券简称：司太立 公告编号：2023-062 浙江司太立制药股份有限公司 关于向关联方转让股权的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）浙江司太立制药股份有限公司（以下简称"公司"）拟将持有的仙居 县聚合金融服务有限公司（统一社会信用代码：91331024MA28GHP78N，以下简 称"聚合金融"或"目标公司"）36%的股权全部转让给公司关联方胡锦生先生， 转让价格为人民币 1,980 万元。 （二）胡锦生担任公司董事，并持有公司股权，根据《上海证券交易所股 票上市规则》的相关规定，胡锦生为公司关联方，本次交易构成关联交易。 （三）本次交易不构成《上市公司重大资产重组管理办法》规定的重大资 产重组。至本次关联交易为止，公司不存在过去12个月内与同一关联人或与不 同关联人之间交易类别相关的关联交易达到3,000万元以上且占上市公司最近一 期经审计净资产绝对值5%以上的情形。本次交易无需提交股东大会审议。 一、关联交易概述 为提高经营管理效率，专注主营业务，公 ...

浙江司太立制药股份有限公司独立董事 关于向关联方转让股权事项的事前认可意见 根据《中华人民共和国公司法》、《关于在上市公司建立独立董事制度的指导意见》、《上海证券交 易所股票上市规则》、《浙江司太立股份有限公司章程》等有关规定，我们作为浙江司太立制药股份有限 公司（以下简称"公司"）的独立董事，我们对公司第五届董事会第三次会议拟审议的《关于向关联方转 让股权的议案》的有关材料进行了认真事前审查，基于独立判断，我们就拟审议的事项出具事前认可意见 如下： （一）《关于向关联方转让股权的议案》 公司向胡锦生转让仙居县聚合金融服务有限公司股权，有利于公司专注主营业务发展，提高管理效率， 符合公司战略发展方向，不存在损害公司及股东利益的情况。公司对本次关联交易所履行的审批、披露程 序符合有关规定。同意将该事项提交公司董事会审议。 独立董事：胡吉明、毛美英、章晓科 2023 年 8 月 17 日 [本页无正文，仅为浙江司太立制药股份有限公司独立董事关于向关联方转让股权事项的事前认可意见之签 字页] 胡吉明 毛美英 章晓科 ...

证券代码：603520 证券简称：司太立 公告编号：2023-063 浙江司太立制药股份有限公司 第五届监事会第三次会议决议公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）浙江司太立制药股份有限公司（以下简称"公司"）第五届监事会第 三次会议于 2023 年 8 月 21 日以现场结合通讯的方式召开，并以现场结合通讯的 方式进行表决。 （四）本次会议由监事会主席郑方卫先生召集并主持。 （五）本次会议召开符合《中华人民共和国公司法》及相关法律、法规、规 范性文件及《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过了《关于向关联方转让股权的议案》 同意公司将持有的仙居县聚合金融服务有限公司 36%的股权转让给公司关 联方胡锦生先生，转让价格为人民 1,980 万元。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 议案具体内容详见公司于 2023 年 8 月 22 日披露的《司太立关于向关联方转 让股权的公告》。 特此公告。 （二）公司已于 2023 年 8 月 1 ...

证券代码：603520 证券简称：司太立 公告编号：2023-036 浙江司太立制药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 05 月 17 日(星期三) 下午 13:00-14:30 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 05 月 10 日(星期三) 至 05 月 16 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stl@starrypharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江司太立制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 565,907,679.16, representing a year-on-year increase of 9.40%[5] - Net profit attributable to shareholders decreased by 88.08% to CNY 9,567,951.36, while the net profit after deducting non-recurring gains and losses fell by 89.80% to CNY 7,456,100.10[5] - Basic and diluted earnings per share were both CNY 0.03, down 87.50% year-on-year[6] - Total operating revenue for Q1 2023 was ¥565,907,679.16, an increase of 9.3% compared to ¥517,298,394.90 in Q1 2022[19] - Net profit for Q1 2023 was ¥9,326,030.26, a decrease of 89.2% from ¥86,622,112.55 in Q1 2022[20] - Total comprehensive income for Q1 2023 was ¥9,563,899.40, a decrease from ¥83,710,512.02 in Q1 2022[21] Cash Flow - The net cash flow from operating activities was negative at CNY -42,083,050.09, an increase in outflow of 55.07% compared to the previous year[5] - Cash flow from operating activities for Q1 2023 was -¥42,083,050.09, an improvement from -¥93,672,558.25 in Q1 2022[21] - The net cash flow from investment activities was -$72,276,230.01, indicating a significant outflow compared to the previous period's -$69,200,922.32[22] - The net cash flow from financing activities was $210,517,413.67, slightly higher than the previous period's $199,520,943.36[22] - The company reported a net increase in cash and cash equivalents of $94,035,983.04, compared to $39,606,515.69 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,523,250,622.47, a 4.17% increase from the end of the previous year[6] - The company's current assets totaled RMB 2,352,090,790.54, up from RMB 2,171,638,504.78, indicating an increase of about 8.29%[14] - The company's total liabilities reached RMB 3,742,472,732.48, compared to RMB 3,530,966,127.81 at the end of 2022, marking an increase of around 5.99%[16] - The total equity attributable to shareholders rose to RMB 1,775,045,938.74 from RMB 1,765,240,118.24, showing a slight increase of about 0.56%[16] Expenses - The company reported a significant increase in sales expenses by 221.76%, primarily due to increased promotional costs[8] - Total operating costs for Q1 2023 were ¥555,018,778.78, up 25.5% from ¥442,145,752.91 in Q1 2022[19] - Research and development expenses increased to ¥34,844,731.55 in Q1 2023, up 24.5% from ¥27,968,697.96 in Q1 2022[19] - Sales expenses rose significantly to ¥18,954,376.69 in Q1 2023, compared to ¥5,890,758.13 in Q1 2022[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 34,672[9] Investment Activities - The company reported an investment loss of ¥1,275,335.52 in Q1 2023, compared to a gain of ¥12,315,000.57 in Q1 2022[20] - Cash received from investment income was $1,573,972.30, while cash received from the disposal of fixed assets was $6,000,000.00[22]

Financial Performance - The company's operating revenue for 2022 was CNY 2,131,239,988.65, representing a 6.57% increase compared to CNY 1,999,916,888.19 in 2021[22]. - The net profit attributable to shareholders of the listed company was a loss of CNY 75,845,700.75, a decrease of 123.43% from a profit of CNY 323,754,754.88 in 2021[22]. - The net cash flow from operating activities was a negative CNY 78,373,916.58, down 115.40% from CNY 508,839,385.25 in the previous year[22]. - Total assets increased by 8.31% to CNY 5,302,180,118.40 at the end of 2022, compared to CNY 4,895,377,815.83 at the end of 2021[22]. - The company's net assets attributable to shareholders decreased by 18.84% to CNY 1,765,240,118.24 from CNY 2,174,978,008.51 in 2021[22]. - The company reported a slight decrease of 0.30% in revenue after excluding non-main business income, totaling CNY 1,867,632,680.20[22]. - The basic earnings per share decreased by 123.40% to -0.22 RMB per share in 2022[24]. - The diluted earnings per share also fell by 123.16% to -0.22 RMB per share[24]. - The weighted average return on equity dropped by 19.85 percentage points to -3.81%[23]. - The net profit after deducting non-recurring gains and losses was -97.94 million RMB, down 131.81% year-on-year[33]. - The gross margin for the pharmaceutical manufacturing segment decreased by 12.88 percentage points to 25.27%[57]. Operational Challenges - The company faced challenges from a complex international environment, including inflation and supply chain disruptions[33]. - The company reported a significant decline in gross margin due to rising raw material prices and pricing constraints from centralized procurement[33]. - The company is focusing on the integration of intermediate, raw materials, and formulations to strengthen its supply chain resilience[35]. - The company is actively pursuing new technologies to lower production costs and improve product yield through ongoing technical improvements[34]. - The company faces operational risks related to raw material price fluctuations, particularly for iodine, which is subject to international market volatility[117]. - The company faces quality risks in raw materials, which could lead to product recalls and decreased demand for its APIs and intermediates[118]. - The transition to formulation sales is challenged by significant price drops due to national centralized procurement policies, impacting profitability for non-winning bidders[119]. - High investment and long cycles in drug R&D present risks, with uncertainties potentially leading to missed market opportunities and declining gross margins[120]. - Environmental and safety production risks are present, with potential penalties for non-compliance with national environmental regulations affecting operational performance[119]. Research and Development - The company invested CNY 134.62 million in R&D, accounting for 6.32% of its revenue[91]. - The company has 276 dedicated R&D personnel, with a PhD and Master's ratio of 13.41%[91]. - The company’s main products, including Iohexol injection and Gadobutrol injection, are currently under active research and registration[91]. - The company has established multiple R&D bases across various locations, including Zhejiang and Shanghai[91]. - The company has over 30 authorized invention patents and has established multiple research centers, enhancing its R&D capabilities in non-ionic contrast agents[49]. Market Strategy - The company aims to become the largest and most comprehensive manufacturer of contrast agent generics globally, focusing on filling domestic gaps in the market[46]. - The company plans to increase international market expansion efforts, targeting regions such as Europe, Southeast Asia, and South America[116]. - The company is transitioning towards digitalization, enhancing automation and intelligence in production processes to improve efficiency[115]. - The company will implement strategies to reduce raw material costs through deeper cooperation with suppliers and expanding procurement channels[114]. - The company is advancing its digital transformation initiatives to improve operational efficiency and reduce labor costs[34]. Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[122]. - The company actively engages with investors through platforms and direct communication to ensure transparency and address inquiries[124]. - The company held one shareholders' meeting during the reporting period, adhering to legal and regulatory requirements[126]. - The company has established a comprehensive internal control system, with no significant deficiencies reported during the period[157]. - The company has committed to a share transfer limit of no more than 25% of total shares held during their tenure, with a six-month restriction post-resignation[183]. Environmental Compliance - The company achieved a total wastewater discharge of 494,697 tons in 2022, with a COD discharge of 139.985 tons[160]. - The company maintained compliance with environmental discharge standards, with no exceedances reported for key pollutants[162]. - The company has established a hazardous waste storage facility with a maximum capacity of 650 tons, complying with environmental protection standards[166]. - The company has implemented a comprehensive environmental risk emergency mechanism, ensuring effective response to environmental incidents[168]. - The company’s wastewater monitoring includes key pollutants such as COD, pH, and ammonia nitrogen, with automatic online monitoring every 2 hours for certain indicators[169]. Shareholder Information - The company plans to distribute a cash dividend of CNY 2 per 10 shares to all shareholders, pending approval at the 2022 annual general meeting[5]. - The total number of shares held by Hu Jingsheng increased from 50,274,000 at the beginning of the year to 70,383,600 at the end of the year, reflecting an increase of 20,109,600 shares due to a capital reserve distribution of 4 shares for every 10 shares held[128]. - The total number of shares held by Hu Jian increased from 44,100,000 to 61,740,000, with an increase of 17,640,000 shares attributed to the same capital reserve distribution[128]. - The total number of shares held by Shen Weiyi increased from 41,800 to 58,520, resulting in an increase of 16,720 shares due to the capital reserve distribution[128]. - The total compensation for Hu Jingsheng was 126.34 million yuan, while Hu Jian received 97.50 million yuan in compensation[128]. Financial Management - The company has engaged in cash asset management with a total amount of 13,000,000 RMB from idle raised funds[199]. - The company has multiple financial management agreements with banks, with amounts of 3,000,000 RMB and varying annualized returns between 3.00% and 3.20%[200]. - The company has a financial management agreement with China Construction Bank for 3,000,000 RMB with an expected return of 3.20%[200]. - The company has a financial management agreement with Bank of China for 3,000,000 RMB with an expected return of 3.20%[200]. - The company has a financial management agreement with Shanghai Pudong Development Bank for 3,000,000 RMB with an expected return of 3.10%[200].

Financial Performance - The company's operating revenue for Q3 2022 was ¥434,607,985.41, a decrease of 4.60% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥44,538,216.17, representing a decline of 169.76% year-on-year[5]. - The basic and diluted earnings per share were both -¥0.13, a decrease of 168.42% compared to the previous year[6]. - Net profit for Q3 2022 was ¥29,153,535.03, a decrease of 86.7% from ¥218,630,537.22 in Q3 2021[22]. - Earnings per share for Q3 2022 were ¥0.06, down from ¥0.64 in Q3 2021[23]. - The company’s total comprehensive income for Q3 2022 was ¥39,623,831.90, a decrease from ¥217,165,669.25 in Q3 2021[23]. Assets and Liabilities - The total assets increased by 8.48% to ¥5,310,467,772.86 compared to the end of the previous year[6]. - Total assets reached ¥5,310,467,772.86, compared to ¥4,895,377,815.83 at the end of 2021[17]. - Total liabilities as of Q3 2022 amounted to ¥3,451,819,907.34, an increase of 28.7% from ¥2,680,840,106.19 in the previous year[19]. - Total equity attributable to shareholders was ¥1,853,005,334.58, down from ¥2,174,978,008.51 in the same period last year[19]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥139,367,076.42, a decrease of 161.42%[6]. - Operating cash inflow for the first three quarters of 2022 was CNY 1,590,851,368, an increase from CNY 1,516,151,908 in the same period of 2021[24]. - Net cash flow from operating activities for Q3 2022 was negative CNY 139,367,076, compared to a positive CNY 226,898,023 in Q3 2021[25]. - Cash outflow from investment activities in Q3 2022 was CNY 581,454,172.83, down from CNY 846,016,744.59 in Q3 2021[25]. - Net cash flow from financing activities for Q3 2022 was CNY 338,145,471.37, compared to a negative CNY 224,849,217.54 in Q3 2021[25]. - Total cash and cash equivalents at the end of Q3 2022 stood at CNY 566,136,329.43, slightly up from CNY 558,313,923.41 at the end of Q3 2021[25]. Inventory and Expenses - The company reported a significant increase in inventory by 47.46%, attributed to rising material prices and unfinished product shipments[10]. - The company experienced a 421.02% increase in selling expenses due to the expansion of its sales team and market promotion efforts[11]. - Total operating costs for the first three quarters of 2022 were ¥1,389,191,306.23, up 33.4% from ¥1,041,893,450.38 in the previous year[21]. - Research and development expenses for the first three quarters of 2022 were ¥95,473,436.89, an increase of 17% compared to ¥81,562,529.85 in 2021[21]. - The company reported a significant increase in sales expenses, which rose to ¥56,572,538.02 from ¥10,858,080.39 in the previous year[21]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 41,918[12]. - The largest shareholder, Hu Jingsheng, holds 70,383,600 shares, representing 20.53% of total shares[13]. Other Information - The company has not disclosed any significant new strategies or product developments during the reporting period[15]. - The company reported a notable increase in prepayments, rising to ¥73,127,465.35 from ¥16,014,257.97[17]. - Long-term equity investments decreased to ¥96,333,551.80 from ¥119,554,727.98[17]. - Cash received from sales of goods and services in the first three quarters of 2022 was CNY 1,282,877,687.53, compared to CNY 1,170,010,655.74 in the same period of 2021[24]. - Cash paid for goods and services in the first three quarters of 2022 was CNY 1,221,638,339.68, significantly higher than CNY 674,196,027.11 in the same period of 2021[24]. - Cash received from investment activities in Q3 2022 totaled CNY 327,534,885.97, down from CNY 711,542,948.80 in Q3 2021[25]. - Cash paid for employee compensation in Q3 2022 was CNY 181,216,557.88, an increase from CNY 153,227,442.22 in Q3 2021[25]. - Cash flow from operating activities in Q3 2022 was impacted by a total outflow of CNY 1,730,218,444.42, compared to CNY 1,289,253,885.09 in Q3 2021[25].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥942.47 million, representing a 10.22% increase compared to ¥855.10 million in the same period last year[20]. - The net profit attributable to shareholders decreased by 58.83% to ¥64.08 million from ¥155.65 million year-on-year[20]. - Basic earnings per share dropped by 58.70% to ¥0.19 from ¥0.46 in the same period last year[21]. - The total operating revenue for the first half of 2022 reached CNY 942,467,743.84, an increase of 10.2% compared to CNY 855,102,492.27 in the same period of 2021[117]. - The total operating costs rose to approximately ¥900.29 million, up from ¥660.48 million, indicating an increase of about 36.3%[118]. - The company reported a total profit of approximately ¥83.06 million, down from ¥198.36 million, which is a decrease of about 58.3%[118]. - The total comprehensive income for the first half of 2022 was approximately ¥74.06 million, down from ¥150.60 million, reflecting a decrease of about 50.8%[119]. Cash Flow and Financial Position - The net cash flow from operating activities fell by 222.74%, resulting in a negative cash flow of ¥183.60 million, primarily due to increased cash payments for raw materials[22]. - The company reported a net cash flow from financing activities of RMB 192,858,723.32, a turnaround from a negative RMB -339,898,455.35 in the same period last year, reflecting increased bank borrowings[39]. - The ending cash and cash equivalents balance for the first half of 2022 was CNY 482,552,548.69, compared to CNY 396,095,607.95 at the end of the first half of 2021, indicating an increase of about 21.8%[125]. - The total liabilities of the company increased to RMB 3,196,262,604.42 from RMB 2,622,570,600.72, representing a rise of about 21.8%[111]. - The company's cash and cash equivalents decreased to RMB 689,696,208.12 from RMB 775,740,000.41, representing a decline of about 11.1%[110]. Assets and Investments - The company's total assets increased by 5.33% to approximately ¥5.16 billion from ¥4.90 billion at the end of the previous year[20]. - The company made equity investments totaling RMB 38 million in various biotechnology and pharmaceutical companies during the reporting period[45]. - The company’s long-term borrowings stood at RMB 730,611,148.94, a slight decrease of 2.14% from RMB 746,554,479.98[42]. - The company’s investment income surged to RMB 28,550,614.31, a remarkable increase of 910.21% from RMB 2,826,204.65 in the previous year[39]. Operational Challenges - The decline in profit was attributed to rising raw material prices and the impact of the COVID-19 pandemic on production and sales in Shanghai[22]. - The company faces operational risks including raw material quality, sales risks due to centralized procurement policies, and high R&D costs[50]. - The company is exposed to policy risks related to drug price adjustments and changes in the national essential drug list, which could impact sales and profitability[52]. Environmental Management - The company reported a total wastewater discharge of 224,137 tons with a COD discharge of 59.240 tons and ammonia nitrogen discharge of 0.65 tons from January to June 2022[61]. - The company has implemented a comprehensive environmental management system, ensuring all pollution control facilities are operational and meet production needs[66]. - The company has a hazardous waste storage facility with a maximum storage capacity of 650 tons, complying with environmental protection standards[66]. Corporate Governance and Compliance - The company has committed to fair and reasonable terms in any related party transactions, avoiding preferential conditions compared to third parties[81]. - The company has confirmed that it will adhere to all relevant laws and regulations regarding related party transactions[81]. - There were no significant litigation or arbitration matters during the reporting period[84]. Shareholder Information - The total share capital increased from 245,016,871 shares to 343,023,619 shares after a cash dividend of 5 yuan per 10 shares and a capital reserve conversion of 4 shares for every 10 shares[93]. - The top two shareholders, Hu Jinsheng and Hu Jian, hold 20.52% and 18.00% of the shares, respectively, with significant pledges on their holdings[100]. - The company has a total of 26,039 common stock shareholders as of the end of the reporting period[98]. Research and Development - Research and development expenses increased by 16.52% to RMB 61,772,227.52, up from RMB 53,013,572.07[39]. - The company has built a strong R&D capability with over 30 authorized invention patents and collaborations with renowned universities and research institutions[34]. Strategic Initiatives - The company is actively expanding its iodine contrast agent formulation business, successfully participating in the fifth batch of national drug centralized procurement[36]. - The company has established a CMO/CDMO business model, leveraging its competitive advantages in specialty APIs to open new growth avenues[26]. - The company is focusing on developing its CMO/CDMO business for active pharmaceutical ingredients and intermediates, leveraging its technical and customer resources[37].

Financial Performance - In 2021, the company's operating revenue reached ¥1,999,916,888.19, representing a 46.29% increase compared to ¥1,367,087,241.13 in 2020[17] - The net profit attributable to shareholders was ¥323,754,754.88, a 35.62% increase from ¥238,729,340.15 in the previous year[17] - The net profit after deducting non-recurring gains and losses was ¥307,864,117.27, up 30.04% from ¥236,753,234.90 in 2020[17] - The net cash flow from operating activities was ¥508,839,385.25, a significant increase of 191.63% compared to ¥174,479,180.11 in 2020[17] - As of the end of 2021, the total assets amounted to ¥4,895,377,815.83, reflecting an 11.10% increase from ¥4,406,335,461.47 at the end of 2020[17] - The net assets attributable to shareholders increased to ¥2,174,978,008.51, a 19.27% rise from ¥1,823,503,185.33 in 2020[17] - The basic and diluted earnings per share increased by 32% to 1.32 RMB per share[18] - The weighted average return on equity decreased by 1.67 percentage points to 16.04%[18] Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥5 per 10 shares and to increase capital by 4 shares for every 10 shares held[4] - The total number of shares held by the chairman, Hu Jinsheng, remained unchanged at 50,274,000 shares, with a pre-tax compensation of 1.28 million CNY for the reporting period[109] - The total number of shares held by the general manager, Hu Jian, also remained unchanged at 44,100,000 shares, with a pre-tax compensation of 1.18 million CNY[109] - The total pre-tax compensation for all directors and supervisors amounted to 6.09 million CNY for the reporting period[111] - The company proposed a cash dividend of 5 yuan per 10 shares (including tax) for the 2021 fiscal year, pending approval at the annual shareholders' meeting[136] Research and Development - The company successfully participated in the national centralized procurement, winning bids for its Iohexol and Iopamidol injection products[29] - The company submitted supplementary materials for iodinated contrast agents and registered an application for gadobutrol injection in December 2021, continuing its R&D efforts in the contrast agent field[30] - A total of 69 patents have been granted or are under review, including 49 invention patents, indicating a strong focus on innovation[31] - The company’s R&D expenses increased by 41.82% to CNY 124,580,729.29, reflecting a commitment to innovation[43] - The company has established five R&D centers and has over 30 authorized invention patents, showcasing its strong R&D capabilities[40] - The company aims to enhance its R&D capabilities and expand its product lines, focusing on X-ray contrast agents and other imaging agents[96] Market and Sales Strategy - The company has established long-term partnerships with major pharmaceutical companies in China, enhancing its market presence and distribution capabilities[36] - The sales model includes direct sales for domestic markets and self-export or distributor sales for international markets, ensuring a stable supply chain[36] - The company aims to become the largest and most comprehensive manufacturer of contrast agents globally, focusing on filling domestic gaps[38] - The company intends to leverage national procurement selections to establish a comprehensive sales network across provinces in China[99] - The company will actively explore international markets, particularly in Europe, Japan, Southeast Asia, the Middle East, and South America[99] Environmental Compliance and Management - The company has established a hazardous waste storage facility with a maximum capacity of 650 tons, compliant with environmental protection standards[150] - The company has implemented an annual self-monitoring plan, with key pollutants monitored every two hours for COD, pH, ammonia nitrogen, and total nitrogen[162] - The company has committed to enhancing its environmental management practices and awareness following the administrative penalty[157] - The company operates a RTO incineration system with a processing capacity of 15,000 standard cubic meters per hour, ensuring effective waste gas treatment[161] - The company has established a comprehensive environmental risk emergency response mechanism to ensure effective handling of environmental incidents[162] Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The board of directors has ensured the authenticity and completeness of the annual report, with no false records or misleading statements[5] - The company has not faced any penalties from securities regulatory authorities in the past three years[119] - The company has not reported any objections raised by directors regarding company matters[123] - The company has implemented a performance assessment system to determine actual remuneration for directors and senior management[116] Financial Management and Investments - The company has approved the use of up to 300 million RMB of idle raised funds for cash management, ensuring the safety and liquidity of investments[190] - The company has engaged in bank wealth management with a total amount of 80 million RMB from idle raised funds, with no overdue amounts[189] - The total guarantee amount (including guarantees to subsidiaries) is 685,516,361.36 RMB, accounting for 31.52% of the company's net assets[187] - The company has made structured deposits with China Bank and Citic Bank, with annualized returns ranging from 1.50% to 4.91%[191] - The company has not disclosed any significant related party transactions or guarantees during the reporting period[186] Social Responsibility - The company donated 15 million yuan during the fourth Taizhou Charity Conference, ranking second in the city for charitable contributions[167] - Over the past three years, the company has donated a total of 7.87 million yuan to various charitable organizations and social causes[167] - The company has implemented a stock incentive plan to attract and retain talented employees, enhancing their motivation and creativity[166]